{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:38:11Z","timestamp":1790743091055,"version":"4.1.0"},"reference-count":116,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Allogeneic stem cell transplantation (allo-SCT) is the preferred curative treatment for several hematological malignancies. The efficacy of allo-SCT depends on the graft-versus-leukemia (GvL) effect. However, the prognosis of patients with relapsed acute myeloid leukemia (AML) following allo-SCT is poor. Donor lymphocyte infusion (DLI) is utilized after allo-SCT in this setting to prevent relapse, to prolong progression free survival, to establish full donor chimerism and to restore the GvL effect in patients with hematological malignancies. Thus, there are different options for the administration of DLI in AML patients. DLI is currently used prophylactically and in the setting of an overt relapse. In addition, in the minimal residual disease (MRD) setting, DLI may be a possibility to improve overall survival. However, DLI might increase the risk of severe life-threatening complications such as graft-versus-host disease (GvHD) as well as severe infections. The transfusion of lymphocytes has been tested not only for the treatment of hematological malignancies but also chronic infections. In this context, manipulated DLI in a prophylactic or therapeutic approach are an option, e.g., virus-specific DLI using different selection methods or antigen-specific DLI such as peptide-specific CD8+ cytotoxic T lymphocytes (CTLs). In addition, T cells are also genetically engineered, using both chimeric antigen receptor (CAR) genetically modified T cells and T cell receptor (TCR) genetically modified T cells. T cell therapies in general have the potential to enhance antitumor immunity, augment vaccine efficacy, and limit graft-versus-host disease after allo-SCT. The focus of this review is to discuss the different strategies to use donor lymphocytes after allo-SCT. Our objective is to give an insight into the functional effects of DLI on immunogenic antigen recognition for a better understanding of the mechanisms of DLI. To ultimately increase the GvL potency without raising the risk of GvHD at the same time.<\/jats:p>","DOI":"10.3390\/jcm9010039","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T05:56:15Z","timestamp":1577166975000},"page":"39","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1256-173X","authenticated-orcid":false,"given":"Jochen","family":"Greiner","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Diakonie Hospital Stuttgart, 70176 Stuttgart, Germany"},{"name":"Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"G\u00f6tz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Bunjes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Wais","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.bmt.1701131","article-title":"T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect","volume":"21","author":"Barrett","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood.V126.23.97.97","article-title":"Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia","volume":"126","author":"Tawara","year":"2015","journal-title":"Blood"},{"key":"ref_6","first-page":"145","article-title":"Expanding the scope of WT1-and cyclin A1-specific TCR gene therapy for AML and other cancers","volume":"143","author":"Perret","year":"2016","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/blood-2013-01-478164","article-title":"Enhanced-affinity murine T-cell receptors for tumor\/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection","volume":"122","author":"Schmitt","year":"2013","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2013.02.005","article-title":"Finding the sweet spot for donor lymphocyte infusions","volume":"19","author":"Yun","year":"2013","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2010.05.005","article-title":"NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies","volume":"16","author":"Alyea","year":"2010","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ijc.31753","article-title":"Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders","volume":"144","author":"Hofmann","year":"2019","journal-title":"Int. J. Cancer J. Int. du Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/sj.leu.2404913","article-title":"FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: Association with disease stage and survival","volume":"21","author":"Gjerdrum","year":"2007","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s12185-013-1436-3","article-title":"Clinical significance of Treg cell frequency in acute myeloid leukemia","volume":"98","author":"Yang","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.leukres.2010.08.010","article-title":"Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease","volume":"35","author":"Laurenti","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.4049\/jimmunol.1200602","article-title":"Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome","volume":"189","author":"Mailloux","year":"2012","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/10245332.2015.1101965","article-title":"Increased regulatory T cells in acute lymphoblastic leukaemia patients","volume":"21","author":"Idris","year":"2016","journal-title":"Hematology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1200\/JCO.2011.41.1116","article-title":"Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation","volume":"31","author":"Hofmann","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2013-04-496844","article-title":"Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)","volume":"122","author":"Greiner","year":"2013","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00262-017-2073-0","article-title":"Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells","volume":"67","author":"Moore","year":"2018","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2014.189","article-title":"Cell-based strategies to manage leukemia relapse: Efficacy and feasibility of immunotherapy approaches","volume":"29","author":"Rambaldi","year":"2015","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbmt.2003.11.003","article-title":"\u03b1-Interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease","volume":"10","author":"Posthuma","year":"2004","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bmt.1701496","article-title":"Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: Impact of infused and residual donor T cells","volume":"22","author":"Verdonck","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/1574888X11666161226150159","article-title":"Current Status of Leukemia Cytotherapy-Exploitation with Immune Cells","volume":"12","author":"Bao","year":"2017","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.bbmt.2015.07.002","article-title":"Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy","volume":"21","author":"Kongtim","year":"2015","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1172\/JCI81229","article-title":"Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts","volume":"125","author":"Bleakley","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2013.08.012","article-title":"Proceedings from the National Cancer Institute\u2019s Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: Part III. Prevention and treatment of relapse after allogeneic transplantation","volume":"20","author":"Porter","year":"2014","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/tan.13005","article-title":"Hematopoietic stem cell transplantation and cellular therapy","volume":"89","author":"Kolb","year":"2017","journal-title":"HLA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.2011.08889.x","article-title":"Alpha interferon augments the graft-versus-leukaemia effect of second stem cell transplants and donor lymphocyte infusions in high-risk paediatric leukaemias","volume":"156","author":"Cooper","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","article-title":"Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party","volume":"25","author":"Schmid","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/ejh.12832","article-title":"Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT","volume":"98","author":"Rautenberg","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/ejh.12647","article-title":"High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation","volume":"96","author":"Marktel","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2018.07.005","article-title":"Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation","volume":"72","author":"Sommer","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00277-017-3185-5","article-title":"Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"97","author":"Schroeder","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.07.010","article-title":"Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation","volume":"49","author":"Ghobadi","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/bmt.2015.10","article-title":"5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft","volume":"50","author":"Steinmann","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2013A retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/bmt.2013.233","article-title":"Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT","volume":"49","author":"Tessoulin","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.bbmt.2016.03.023","article-title":"Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant","volume":"22","author":"Motabi","year":"2016","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbmt.2015.07.037","article-title":"Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies","volume":"22","author":"Guieze","year":"2016","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/asheducation-2017.1.708","article-title":"Cells to prevent\/treat relapse following allogeneic stem cell transplantation","volume":"2017","author":"Dietz","year":"2017","journal-title":"Hematol. Educ. Program Am. Soc. Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1182\/blood-2015-12-629089","article-title":"Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies","volume":"127","author":"Sun","year":"2016","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2010.08.031","article-title":"Natural killer cell education and tolerance","volume":"142","author":"Orr","year":"2010","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2017-08-752162","article-title":"The potential role of gammadelta T cells after allogeneic HCT for leukemia","volume":"131","author":"Handgretinger","year":"2018","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","article-title":"Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited","volume":"36","author":"Deol","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: Methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.15881","article-title":"G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients","volume":"186","author":"Schneidawind","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/ctr.12404","article-title":"The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Zhao","year":"2014","journal-title":"Clin. Transplant."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/bmt.2017.193","article-title":"Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy","volume":"52","author":"Goldsmith","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bbmt.2017.02.012","article-title":"Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program","volume":"23","author":"Miyamoto","year":"2017","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00277-017-2960-7","article-title":"Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"96","author":"Mo","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15691","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia-a matched pair analysis by the Acute Leukaemia Working Party of EBMT","volume":"184","author":"Schmid","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-018-3482-7","article-title":"Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies","volume":"98","author":"Gao","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Cauchois, R., Castagna, L., Pagliardini, T., Harbi, S., Calmels, B., Bramanti, S., Granata, A., Lemarie, C., Maisano, V., and Legrand, F. (2018). Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: A retrospective bicentric analysis of serial infusions of increasing doses of CD3(+) cells. Br. J. Haematol.","DOI":"10.1111\/bjh.15544"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bmt.2013.111","article-title":"Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL","volume":"49","author":"Eefting","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood-2002-10-3263","article-title":"Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: An EBMT megafile analysis","volume":"102","author":"Ljungman","year":"2003","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"32579","DOI":"10.18632\/oncotarget.8691","article-title":"Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT","volume":"7","author":"Xuan","year":"2016","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood.V124.21.3892.3892","article-title":"Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients","volume":"124","author":"Michallet","year":"2014","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: Results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.bbmt.2012.05.003","article-title":"Allogeneic hematopoietic cell transplantation in patients age 60\u201370 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: Comparison with patients lacking donors who received azacitidine","volume":"18","author":"Platzbecker","year":"2012","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ejh.12591","article-title":"Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: Prognostic factors and clinical outcomes","volume":"96","author":"Mo","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bbmt.2016.11.002","article-title":"Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate-or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"23","author":"Malard","year":"2017","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"41ra52","DOI":"10.1126\/scitranslmed.3001302","article-title":"CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation","volume":"2","author":"Maury","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2003-05-1513","article-title":"Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: Toxicity, chimerism, and disease responses","volume":"103","author":"Peggs","year":"2004","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jim.2016.04.010","article-title":"A global look into human T cell subsets before and after cryopreservation using multiparametric flow cytometry and two-dimensional visualization analysis","volume":"434","author":"Lemieux","year":"2016","journal-title":"J. Immunol. Methods"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.bbmt.2018.04.018","article-title":"Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation","volume":"24","author":"Groger","year":"2018","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.V94.4.1201","article-title":"Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes","volume":"94","author":"Falkenburg","year":"1999","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.exphem.2010.07.002","article-title":"Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions","volume":"38","author":"Wang","year":"2010","journal-title":"Exp. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bae, J., Samur, M., Richardson, P., Munshi, N.C., and Anderson, K.C. (2019). Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8(+) cytotoxic T lymphocytes: Immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia.","DOI":"10.1038\/s41375-019-0414-z"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbmt.2014.11.002","article-title":"Recent advances in cytomegalovirus: An update on pharmacologic and cellular therapies","volume":"21","author":"Boeckh","year":"2015","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM198207013070102","article-title":"Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients","volume":"307","author":"Quinnan","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.V78.5.1373.1373","article-title":"Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease","volume":"78","author":"Reusser","year":"1991","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.1128\/JVI.74.17.8140-8150.2000","article-title":"Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors","volume":"74","author":"Gillespie","year":"2000","journal-title":"J. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bbmt.2017.08.028","article-title":"Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients","volume":"24","author":"Ma","year":"2018","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/infdis\/153.3.478","article-title":"Risk factors for cytomegalovirus infection after human marrow transplantation","volume":"153","author":"Meyers","year":"1986","journal-title":"J. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadopoulos","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","article-title":"Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells","volume":"115","author":"Moosmann","year":"2010","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1399-3062.2009.00411.x","article-title":"Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: A comprehensive review of reported cases","volume":"11","author":"Styczynski","year":"2009","journal-title":"Transpl. Infect. Dis. Off. J. Transplant. Soc."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2018-99-119314","article-title":"Very Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy for Prevention of Viral Infection after Allogeneic T Cell Depleted Stem Cell Transplantation","volume":"132","author":"Muranski","year":"2018","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5144\/1658-3876.2011.149","article-title":"Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation","volume":"4","author":"Kanate","year":"2011","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2141.2003.04228.x","article-title":"T-cell depletion with Campath-1H \u201cin the bag\u201d for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival","volume":"121","author":"Chakrabarti","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-018-0668-3","article-title":"Ex Vivo and In Vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: On behalf of the ALWP of the EBMT and the MSKCC","volume":"11","author":"Malard","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3324\/haematol.2017.176107","article-title":"Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: A position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"102","author":"Lee","year":"2017","journal-title":"Haematologica"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: Dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"174ra127","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nm.3100","article-title":"Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation","volume":"19","author":"Ceberio","year":"2013","journal-title":"Nat. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1182\/blood-2011-11-364091","article-title":"Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity","volume":"119","author":"Stenger","year":"2012","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2017.77.1774","article-title":"Fine-Tuning Antithymocyte Globulin Dosing and Harmonizing Clinical Trial Design","volume":"36","author":"Boelens","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: A multicentre, retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2012.41.7071","article-title":"Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation","volume":"30","author":"Pasquini","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Kanakry, C.G., Coffey, D.G., Towlerton, A.M., Vulic, A., Storer, B.E., Chou, J., Yeung, C.C., Gocke, C.D., Robins, H.S., and O\u2019Donnell, P.V. (2016). Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight, 1.","DOI":"10.1172\/jci.insight.86252"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2015.133","article-title":"Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients","volume":"50","author":"Yew","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Van Bergen, C.A., van Luxemburg-Heijs, S.A., de Wreede, L.C., Eefting, M., von dem Borne, P.A., van Balen, P., Heemskerk, M.H., Mulder, A., Claas, F.H., and Navarrete, M.A. (2017). Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response. J. Clin. Investig.","DOI":"10.1172\/JCI86175"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41590-018-0054-x","article-title":"Publisher Correction: Human gammadelta T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection","volume":"19","author":"Ravens","year":"2018","journal-title":"Nat. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/1\/39\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:44:59Z","timestamp":1760190299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/1\/39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["jcm9010039"],"URL":"https:\/\/doi.org\/10.3390\/jcm9010039","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,23]]}}}